menu toggle

Q&A – Future challenges and predictions for CGT patient focused solutions

By AmerisourceBergen

Dale Hanna, Director, Cell and Gene Therapy (CGT) at AmerisourceBergen, partners with Dr Matthew Lakelin, Vice President, Scientific Affairs and Product Development at TrakCel, for a Q&A session. Together, they explore upcoming challenges and predictions for patient-centric solutions within the CGT field. 
CGT Patient services

They delve into sector-specific challenges, both current and anticipated in the near future, and examine the significant advantages of integrating patient hub services with cell orchestration, underscoring why developers should integrate these components into their digital supply chain.

Topics:
Cell and gene therapy

Related Content

Manufacturers

Essential guide to cell and gene therapy (CGT)  commercialization

Inverted color AmerisourceBergen icon
AmerisourceBergen
April 2024
Rainbow-Abstract

Manufacturers

Opportunities and pain points for CGT innovation and market access

headshot
Lung-I Cheng
Biopharma Services
February 2024
Cell and gene therapy consultants

Manufacturers

Avoiding CGT commercialization pitfalls

headshot
Lung-I Cheng
Biopharma Services
December 2023
pre-launch